Source: European Medicines Agency (EU) Revision Year: 2022 Publisher: Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland
Votubia 1 mg dispersible tablets.
Votubia 2 mg dispersible tablets.
Votubia 3 mg dispersible tablets.
Votubia 5 mg dispersible tablets.
| Pharmaceutical Form |
|---|
|
Dispersible tablet. Votubia 1 mg dispersible tablets: White to slightly yellowish, round, flat tablets of approximately 7.1 mm in diameter, with a bevelled edge and no score, engraved with “D1” on one side and “NVR” on the other. Votubia 2 mg dispersible tablets: White to slightly yellowish, round, flat tablets of approximately 9.1 mm in diameter, with a bevelled edge and no score, engraved with “D2” on one side and “NVR” on the other. Votubia 3 mg dispersible tablets: White to slightly yellowish, round, flat tablets of approximately 10.1 mm in diameter, with a bevelled edge and no score, engraved with “D3” on one side and “NVR” on the other. Votubia 5 mg dispersible tablets: White to slightly yellowish, round, flat tablets of approximately 12.1 mm in diameter, with a bevelled edge and no score, engraved with “D5” on one side and “NVR” on the other. |
Each dispersible tablet contains 1 mg everolimus.
Excipient with known effect: Each dispersible tablet contains 0.98 mg lactose.
Each dispersible tablet contains 2 mg everolimus.
Excipient with known effect: Each dispersible tablet contains 1.96 mg lactose.
Each dispersible tablet contains 3 mg everolimus.
Excipient with known effect: Each dispersible tablet contains 2.94 mg lactose.
Each dispersible tablet contains 5 mg everolimus.
Excipient with known effect: Each dispersible tablet contains 4.90 mg lactose.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Everolimus |
Everolimus is a selective mTOR (mammalian target of rapamycin) inhibitor. mTOR is a key serine-threonine kinase, the activity of which is known to be upregulated in a number of human cancers. |
| List of Excipients |
|---|
|
Butylated hydroxytoluene (E321) |
Aluminium/polyamide/aluminium/PVC perforated unit-dose blister containing 10 × 1 dispersible tablets.
Votubia 1 mg dispersible tablets: Packs containing 30 × 1 dispersible tablets.
Votubia 2 mg dispersible tablets: Packs containing 10 × 1, 30 × 1 or 100 × 1 dispersible tablets.
Votubia 3 mg dispersible tablets: Packs containing 30 × 1 or 100 × 1 dispersible tablets.
Votubia 5 mg dispersible tablets: Packs containing 30 × 1 or 100 × 1 dispersible tablets.
Not all pack sizes may be marketed.
Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland
Votubia 1 mg dispersible tablets:
EU/1/11/710/016
Votubia 2 mg dispersible tablets:
EU/1/11/710/009-011
Votubia 3 mg dispersible tablets:
EU/1/11/710/012-013
Votubia 5 mg dispersible tablets:
EU/1/11/710/014-015
Date of first authorisation: 02 September 2011
Date of latest renewal: 23 July 2020
| Drug | Countries | |
|---|---|---|
| VOTUBIA | Austria, Cyprus, Estonia, Spain, Finland, France, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Romania, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
